Ontruzant is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Ontruzant is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameOntruzant
Authorized generictrastuzumab
Regular generictrastuzumab
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Ontruzant?
The original
–
–

Brand nameThe maker’s card

Organon Co-pay Assistance Program

Savings card from Organon

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $5 per prescription and/or administration

Sign up on organonaccessprogram.com 

Or call 1-866-809-9515.

In the maker’s words

“RENFLEXIS® (infliximab-abda) and ONTRUZANT® (trastuzumab-dttb): Patient may pay as little as $5 per prescription and/or administration.”

From the maker’s offer on organonaccessprogram.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Ontruzant itself, from the same company, sold without the brand name, and usually for less. For now Ontruzant is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Ontruzant is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

Ontruzant is a HER2/neu receptor antagonist indicated in adults for:

  • The treatment of HER2-overexpressing breast cancer.
  • The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.

Source: the FDA label for Ontruzant (Organon LLC), April 20, 2026. Full label on DailyMed 

Good to know